Acrinova AB Class A (ACRI.A) AI Stock Analysis

• Market Cap: kr745.04M
• Dividend Yield: 11.29%
• Average Volume (3M): 6.15K
• Price to Earnings (P/E): 17.6
• Beta (1Y): -0.17
• Revenue Growth: 6.55%
• EPS Growth: 1402.99%
• Country: SE
• Employees: 8
• Sector: Real Estate
• Sector Strength: 53
• Industry: Real Estate - Diversified
• EPS (TTM): 0.01
• Shares Outstanding: 23,749,575
• 10 Day Avg. Volume: 16,690
• 30 Day Avg. Volume: 6,153
• PEG Ratio: 0.05
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 4.29
• P/FCF Ratio: 54.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr13.49
• Price Target Upside: 7.93% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: kr13.50 ▲(8.00% Upside)

Acrinova AB Class A's overall stock score is driven by strong valuation metrics, particularly its high dividend yield, which is appealing to income investors. However, technical indicators suggest a lack of bullish momentum, and financial performance highlights challenges in cash flow generation and return on equity. The absence of significant earnings call insights or corporate events leaves the focus on these core components.

Acrinova AB Class A Business Overview & Revenue Model

Company Description

Acrinova AB (publ) owns, develops, and manages real estate properties in southern Sweden. The company offers condominiums, premises for trade and offices, preschools, schools, and nursing homes. It comprises of 27 properties in the Oresund and focuses on properties, such as warehouses and logistics. Acrinova AB (publ) was founded in 2014 and is headquartered in Malmo, Sweden.

How the Company Makes Money

Acrinova generates revenue primarily through the sale of its diagnostic products and therapeutic solutions to hospitals, clinics, and healthcare providers. The company has established key partnerships with pharmaceutical companies and research institutions, allowing it to expand its product offerings and enhance its research capabilities. Additionally, Acrinova may receive funding through grants and collaborations for research and development initiatives, contributing to its overall earnings. The company also explores licensing agreements for its technologies, which can provide significant income streams as they gain regulatory approval and market adoption.

Acrinova AB Class A Financial Statement Overview

Summary

Acrinova AB Class A demonstrates strong revenue growth and improving profitability, with a healthy gross profit margin. However, challenges in cash flow generation and a low return on equity indicate areas for improvement.

Income Statement

Acrinova AB Class A shows strong revenue growth with a TTM increase of 88.8%, indicating robust expansion. The gross profit margin remains healthy at 68.3%, and the net profit margin has improved to 29.9% TTM, reflecting enhanced profitability. However, the EBIT margin has decreased from previous highs, suggesting potential cost pressures or investment in growth.

Balance Sheet

The company's debt-to-equity ratio is 1.09 TTM, indicating moderate leverage, which is typical for the real estate industry. Return on equity is relatively low at 5.03%, suggesting limited efficiency in generating returns from equity. The equity ratio is stable, reflecting a balanced capital structure but with room for improvement in profitability.

Cash Flow

Free cash flow growth is negative at -35.5% TTM, highlighting challenges in cash generation. The operating cash flow to net income ratio is low at 0.09, indicating potential issues in converting income into cash. However, the free cash flow to net income ratio is improving, suggesting better cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	161.38M	159.70M	147.08M	130.53M	101.95M	109.45M
Gross Profit	110.29M	109.32M	100.71M	89.43M	72.61M	78.85M
EBITDA	93.10M	106.81M	73.76M	55.86M	193.68M	30.98M
Net Income	48.23M	35.91M	7.76M	79.34M	153.16M	42.74M
Balance Sheet
Total Assets	2.10B	2.19B	2.16B	2.10B	1.83B	1.01B
Cash, Cash Equivalents and Short-Term Investments	34.03M	81.15M	43.06M	28.31M	74.66M	47.19M
Total Debt	1.03B	1.08B	1.09B	995.69M	798.74M	461.79M
Total Liabilities	1.17B	1.23B	1.22B	1.15B	956.25M	538.24M
Stockholders Equity	938.13M	962.26M	946.92M	941.29M	874.99M	476.24M
Cash Flow
Free Cash Flow	18.09M	12.53M	-77.69M	-28.75M	70.69M	31.46M
Operating Cash Flow	67.29M	61.06M	71.23M	-23.76M	79.90M	33.98M
Investing Cash Flow	-225.94M	-87.75M	-149.53M	-204.88M	-635.12M	-186.83M
Financing Cash Flow	134.53M	64.78M	93.05M	182.30M	582.69M	142.89M

Acrinova AB Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACRI.A, the sentiment is Negative. The current price of 12.5 is below the 20-day moving average (MA) of 12.97, below the 50-day MA of 12.74, and above the 200-day MA of 10.46, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 47.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACRI.A.

Acrinova AB Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACRI.A	66 Neutral	kr745.04M	17.63	5.10%	11.29%	6.55%	1402.99%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
GPG	64 Neutral	kr1.74B	13.55	―	1.16%	-0.16%	―
STUDBO	64 Neutral	kr1.25B	5.00	―	―	13.00%	―
ACRI.B	60 Neutral	kr762.83M	14.86	―	13.33%	6.55%	1402.99%